LR 103
Alternative Names: LR-103Latest Information Update: 31 Mar 2022
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Antineoplastics; Antipsoriatics
- Mechanism of Action Calcitriol receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Hyperparathyroidism; Psoriasis
Most Recent Events
- 28 Mar 2011 Discontinued - Phase-I for Cancer in USA (PO)
- 28 Mar 2011 Discontinued - Preclinical for Hyperparathyroidism in USA (unspecified route)
- 28 Mar 2011 Discontinued - Preclinical for Psoriasis in USA (PO)